biology

Voxelotor

Voxelotor is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Voxelotor rather than just read about it. In short: Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator.

Key takeaways

Voxelotor belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Voxelotor to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Voxelotor from memory before moving on to harder problems.

Reference excerpt

Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator. Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. It initially appeared to have an acceptable safety profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity noted in clinical trials. It was developed by Global Blood Therapeutics, a subsidiary of Pfizer. In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those aged twelve years of age and older. The US Food and Drug Administration considers it to be a first-in-class medication. In December 2021, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those aged four to eleven years. In September 2024, Pfizer announced a voluntary withdrawal of voxelotor from all global markets due to concerns regarding the potential for severe safety events, including fatalities.

Side effects Common side effects include headache, diarrhea, abdominal pain, nausea, fatigue, rash and pyrexia (fever).

History Voxelotor was granted accelerated approval by the US Food and Drug Administration (FDA) in November 2019. The FDA granted the application for voxelotor fast track designation and orphan drug designation. The approval of voxelotor was based on the results of a clinical trial with 274 participants with sickle cell disease. The FDA granted the approval of Oxbryta to Global Blood Therapeutics.

Society and culture

Legal status In December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oxbryta, intended for the treatment of hemolytic anemia due to sickle cell disease. The applicant for this medicinal product is Global Blood Therapeutics Netherlands B.V. Voxelotor (Oxbryta) was approved for medical use in the European Union in February 2022. In September 2024, the CHMP recommended suspending the marketing authorization for voxelotor (Oxbryta). The CHMP described this recommendation as a precaution while a review of additional clinical trial data was proceeding. The CHMP review of clinical trial data began in July 2024, following concerns in two ongoing placebo-controlled clinical trials that raised the possibility that the drug's benefit risk ratio was no longer favorable, due to possibly related excess deaths. The CHMP also cited observational studies which found a higher rate of painful vaso-occlusive crises during treatment with voxelotor than the subjects had before starting the medicine. In October 2025, the CHMP recommended that the marketing authorization of the sickle cell disease medicine Oxbryta remain suspended. Following its assessment, the CHMP concluded that the benefits of the medicine no longer outweigh its risks. The review was started after data showed a higher number of deaths with Oxbryta than with placebo (a dummy treatment) in one clinical trial and a higher-than-anticipated number of deaths in another trial. In September 2024, Pfizer announced a voluntary withdrawal of voxelotor from all global markets due to concerns regarding the potential for severe safety events, including fatalities.

References

Illustrations

Worked examples

Example 1 — a first encounter with Voxelotor

Start with the simplest possible case. Write down what Voxelotor claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Voxelotor before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Voxelotor ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Voxelotor

In research: Voxelotor appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Voxelotor in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Voxelotor is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Pfizer, Orphan drugs, Sickle-cell disease, so understanding it makes those chapters shorter.
In everyday life: Look for Voxelotor outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Voxelotor” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Voxelotor in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Voxelotor means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Voxelotor out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Voxelotor in simple terms?

Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. Voxelotor is the first hemoglobin oxygen-affinity modulator.

Why does Voxelotor matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Voxelotor?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Voxelotor.